Target enrollment for a Phase 1b clinical study assessing the safety and tolerability of GT-02287 in people with Parkinson’s disease is complete, three months ahead of the original goal, the therapy’s developer said. After enrolling the first 16 participants, the Phase 1b clinical trial (NCT06732180) is recruiting up…
People in the prodromal, or presymptomatic, stage of Parkinson’s disease show increased immune activity, with T cells targeting the proteins PINK1 and alpha-synuclein at levels similar to those seen in patients already diagnosed with the neurodegenerative condition, a new study reports. These two proteins — PINK1 and alpha-synuclein —…
BioVie’s ongoing SUNRISE-PD clinical trial of bezisterim in early Parkinson’s disease uses a hybrid, decentralized approach to center patient experience and promote accessibility, according to the company. Parkinson’s disease patients often face barriers to accessing specialized care and participating in clinical trials due to delayed diagnosis, limited mobility, and…
A trio of prominent Parkinson’s disease advocacy groups are calling on the U.S. federal government to provide strong funding and support for the National Institutes of Health (NIH) — a federal agency that is a major driver of biomedical research around the world. The American Parkinson Disease Association,…
Copper supplementation that reaches the brain reduces the signs and symptoms of Parkinson’s disease in a mouse model, a study found. Researchers found that copper restored the function of SOD1, an antioxidant enzyme that’s prone to misfolding and forming toxic clumps, impairing the function of dopamine-producing nerve cells that…
Neuron23 has dosed the first participant in its Phase 2 clinical trial of NEU-411, an investigational treatment for early Parkinson’s disease that targets overactivity in the LRRK2 enzyme. The therapy may benefit individuals with genetic mutations or variations in the LRRK2 gene, which is a key contributor and…
People with Parkinson’s disease have altered levels of certain fat molecules, known as lipids, in their brains, and this may play a role in disease development and progression, a new study from the U.S. reports. The researchers used postmortem brain tissue samples to analyze changes in lipids in 40…
A three-year grant from Parkinson Canada will allow a Canadian researcher to investigate the mechanisms by which a recently found mutation in the RAB32 gene is linked to Parkinson’s disease. The $135,000 grant will allow Jay Penney, PhD, associate professor at the University of Prince Edward Island in…
A new method that uses artificial intelligence (AI) to analyze the smell of earwax may help detect Parkinson’s disease, a new study from China reports. This affordable approach could one day be used to screen people for early signs of Parkinson’s, making it easier to catch the disease before…
VTX3232, an NLRP3 inhibitor being developed by Ventyx Biosciences as a treatment for Parkinson’s disease, was found to be safe and well tolerated after nearly one month of daily dosing in a clinical trial involving people with early-stage disease, according to the company. With these results, VTX3232 met…
Get regular updates to your inbox.
